Consensus Statement for Standard of Care in Spinal Muscular Atrophy

  title={Consensus Statement for Standard of Care in Spinal Muscular Atrophy},
  author={Ching H. Wang and Richard S. Finkel and Enrico Silvio Bertini and Mary K. Schroth and Anita Simonds and Brenda L Y Wong and Annie Aloysius and Leslie Morrison and Marion Main and Thomas O. Crawford and Anthony Trela},
  journal={Journal of Child Neurology},
  pages={1027 - 1049}
Spinal muscular atrophy is a neurodegenerative disease that requires multidisciplinary medical care. Recent progress in the understanding of molecular pathogenesis of spinal muscular atrophy and advances in medical technology have not been matched by similar developments in the care for spinal muscular atrophy patients. Variations in medical practice coupled with differences in family resources and values have resulted in variable clinical outcomes that are likely to compromise valid measure of… 

Figures and Tables from this paper

Spinal Muscular Atrophy— Summary for Nutritional Care: The Consensus Statement for Standard of Care in Spinal Muscular Atrophy
This article provides a summary and overview of the gastrointestinal-/nutrition-related standard of care for patients with spinal muscular atrophy and identifies topics in nutrition care in need of further study.
Clinical Outcome Measures in Spinal Muscular Atrophy
An evidence-based review of available clinical outcome measures in spinal muscular atrophy finds that consensus is imperative to facilitate collaboration and explore the ability of these measures to identify the therapeutic effect of disease-modifying agents.
Spinal muscular atrophy: Advances in research and consensus on care of patients
Three groups of compounds have been identified as therapeutic candidates for SMA, and one group was identified before the molecular genetics of SMA was understood, chosen on the basis of their effectiveness in similar neurologic disorders.
Spinal Muscular Atrophy Type I
How autonomy, beneficence/non-maleficence, noncoercion, social benefit, and equipoise can be maintained when a predefined level of supportive care is proposed, for participation in a clinical trial is discussed.
The Experience of Families With Children With Spinal Muscular Atrophy Type I Across Health Care Systems
Spinal muscular atrophy type I is a genetic disease characterized by degeneration of spinal cord motor neurons resulting in weakness, technology dependence and early demise. While the newly approved
General issues of spinal muscular atrophy (scientific review). Etiology, clinical features, approaches in rehabilitation and orthopedic treatment
A more detailed study of etiological factors, pathogenesis and clinical features of spinal muscular atrophy will allow a more extensive look at the problems of this disease in order to better understand the possible methods of diagnosis and treatment of patients with this pathology.


Outcome measures for pediatric spinal muscular atrophy.
A tool for motor function may be more useful in clinical trials of childhood SMA than one for quantitative muscle strength.
Spinal muscular atrophy: experience in diagnosis and rehabilitation management of 60 patients.
Although the life span with Type I SMA (Werdnig-Hoffmann disease) may be short, children with the disease can be made more comfortable with appropriate medical care and parental support.
Reliability of 4 outcome measures in pediatric spinal muscular atrophy.
The Gross Motor Function Measure, pulmonary function tests, quantitative muscle testing, and quality of life are reliable outcome measures for clinical trials in pediatric spinal muscular atrophy.
Respiratory support in spinal muscular atrophy type I: a survey of physician practices and attitudes.
A wide variation in physician practice is found regarding the mechanical ventilation of patients with SMA type I, and it is suggested that physician training and attitudes affect recommendations regarding mechanical ventilation and ultimately family decision making.
Spinal Muscular Atrophy: Survival Pattern and Functional Status
The age of disease onset is defined as the age in which the first abnormalities were obvious from the medical records or from the descriptions of the parents about the first signs of weakness, eg, age of achievement of certain motor milestones or loss of functions.
Challenges and opportunities in clinical trials for spinal muscular atrophy
The authors sought to address the challenges and opportunities for testing new therapies for SMA and several candidates including histone deacetylase (HDAC) inhibitors are under consideration for further evaluation.
Process measures and patient/parent evaluation of surgical management of spinal deformities in patients with progressive flaccid neuromuscular scoliosis (Duchenne's muscular dystrophy and spinal muscular atrophy).
It is indicated that spinal fusion with segmental spinal instrumentation benefits most patients with Duchenne's muscular dystrophy or spinal muscular atrophy with spinal deformities in terms of all categories assessed, even though these diseases have a progressively deteriorating course.